Skip to content
lifestyle.ketodash.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
NurExone Biologic Inc
NurExone Announces Annual General and Special Meeting to Consider Share Consolidation in Support of U.S. Capital Markets Strategy
August 21, 2026
NurExone Announces Closing of C$1,066,078 Private Placement
August 20, 2026
NurExone Reports New Preclinical Tissue-Analysis Data Supporting Potential Neuroprotective Effect of ExoPTEN in Acute Spinal Cord Injury Animal Model
August 14, 2026
NurExone Announces Binding MOU with Made Scientific for U.S. GMP Manufacturing and Commercial Supply Partnership
August 12, 2026
NurExone Launches Bioprocess Optimization Initiative to Support Commercial and Clinical Readiness
July 30, 2026
Corporate Updates – NurExone appoints Mr. David Stolick to the Board of Directors
July 28, 2026
Australian Patent Granted to NurExone Covering Stem Cell-Derived Exosome Production
May 20, 2026
NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update
April 16, 2026
NurExone Biologic’s U.S. Subsidiary Exo-Top and Florida-Based BioXtek Sign Strategic LOI for Exosome Manufacturing and Commercialization
April 7, 2026
NurExone Receives First Place in Healthcare at BOLD Awards VII and Engages Investor Brand Network to Support Awareness Strategy
April 1, 2026
1
2
Next Page
→